An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320
This study is recruiting at 11 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Bipolar I Disorder
- Mania
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Neurocrine Biosciences
- Last updated on ClinicalTrials.gov
- September 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Neurocrine Clinical Site · Little Rock, AR
California · 3
- Neurocrine Clinical Site · Cerritos, CA
- Neurocrine Clinical Site · Garden Grove, CA
- Neurocrine Clinical Site · San Diego, CA
Florida · 1
- Neurocrine Clinical Site · Hollywood, FL
Georgia · 1
- Neurocrine Clinical Site · Atlanta, GA
Maryland · 1
- Neurocrine Clinical Site · Gaithersburg, MD
New Jersey · 1
- Neurocrine Clinical Site · Marlton, NJ
New York · 1
- Neurocrine Clinical Site · Staten Island, NY
Texas · 2
- Neurocrine Clinical Site · Austin, TX
- Neurocrine Clinical Site · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.